PRPO - Precipio, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
-0.0250 (-12.35%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2025
Bid0.1770 x 1800
Ask0.1847 x 800
Day's Range0.1750 - 0.2100
52 Week Range0.1500 - 1.7500
Avg. Volume1,989,367
Market Cap8.585M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateFeb 18, 2019 - Feb 21, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Precipio 2018 Revenues Increase 66% over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability

    Furthermore, fourth quarter financials demonstrated continuous movement towards the company’s target of profitability. Key metrics demonstrate the company’s ongoing improvement of its financial performance, with YoY revenue growth alongside the reduction of costs, to ensure that its continuous growth translates into bottom-line results. The company implemented substantial cost-cutting measures in the second half of 2018, the results of which have created a positive impact on the company’s fourth quarter financials.

  • GlobeNewswire19 days ago

    Precipio Gains Recognition on NY Radio Station WHPC Show “My Hometown” As Innovator Battling Cancer Misdiagnosis

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced a recent radio show interview of Ilan Danieli, Precipio’s CEO, on the New York Nassau Community College Radio station. The interview addressed the problem of cancer misdiagnosis, offered thoughts on ways patients can become aware of this problem, and discussed potential options patients and their physicians have to battle this problem. On his show “My Hometown”, veteran radio talk show host Bill Horan interviewed Ilan Danieli to discuss the scope of the problem of cancer misdiagnosis, some of the causes of this phenomenon, and the work the team at Precipio is doing to help physicians and their patients obtain an accurate diagnosis.

  • GlobeNewswirelast month

    Makati Medical Center in the Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology for Liquid Biopsies

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that Makati Medical Center (MakatiMed) in Manila, the Philippines, has placed its first order for ICE COLD-PCR (ICP) as part of its agreement to serve as the exclusive central laboratory in the Philippines for Precipio’s ICP liquid biopsy technology.

  • ACCESSWIRElast month

    Best Bounces to Play the Rally

    HENDERSON, NV / ACCESSWIRE / January 14, 2019 / With the market rallying this week, several oversold stocks are starting to make solid gains. We've found a few stocks that look set up to continue this ...

  • GlobeNewswirelast month

    Precipio Announces First US Government Customer for ICE COLD-PCR™ Mutation Enrichment Technology

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has been approved by the United States Department of Defense (DoD) as a domestic vendor within the Foundation for the Advancement of military medicine. Approval as a vendor will enable DoD funded medical centers to utilize Precipio ICE COLD-PCR (ICP) technology in mutation testing for both active duty as well as military veterans. A hospital within the DoD evaluated several technologies including the competing Droplet Digital PCR (ddPCR), and ultimately decided that Precipio’s ICE-COLD PCR (ICP) enrichment technology for liquid biopsies was to be used at its facility.

  • GlobeNewswirelast month

     Precipio Files Patent for HemeScreen™, its Novel Molecular Assay

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the filing of a patent for its proprietary HemeScreen panel. The panel incorporates a novel method for analyzing four key genes typically evaluated for mutations in patients with hematologic malignancies. In 2016, The World Health Organization (WHO) published guidelines recommending the testing of the JAK2 (V617F mutation), JAK2 Exon 12, MPL and CALR genes as part of the evaluation for patients suspected to have Myelodysplastic Syndrome (MDS) and Myeloproliferative Disorders (MPD), two of the most common hematologic (blood-related) cancers.

  • GlobeNewswire2 months ago

    Precipio Reports Strong Mid-Quarter Growth

    Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that based on metrics observed in its October and November revenue numbers (quarter-to-date), the company is on track for continued strong Quarter-over-Quarter revenue growth. Preliminary (unaudited) pathology services revenues in November increased 16% from October, keeping in line with expected Q4 total quarterly revenue growth in excess of 25% over Q3, driven by strong growth in both clinical revenue and pharma services. Additionally, the number of ordering physicians increased by a healthy 30% for the same period, and case volume increased, indicating strong adoption of the company’s offering and a promising pipeline of future revenue growth.

  • GlobeNewswire2 months ago

    Precipio Announces $1.2 Million Securities Purchase Agreement With Participation from Members of Its Board of Directors, and other Investors

    Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has entered into a $1.2 million Securities Purchase Agreement with several existing investors, as well as two members of its Board of Directors. “We are encouraged by the endorsement of our investors, and in particular the support of two members of our Board of Directors, who have again demonstrated their support of the company as we continue to grow the business, and refine our suite of products and services for the cancer diagnostics market,” said Ilan Danieli, CEO of Precipio. On November 29, 2018, the Company entered into an agreement which provides for the issuance of up to $1.2M in additional notes, together with applicable warrants.

  • ACCESSWIRE3 months ago

    The Reason Healthcare Stocks Are Being Called Home By Investors

    CORAL GABLES, FL / ACCESSWIRE / November 27, 2018 / Healthcare stocks helped boost the stock market rally on Monday. Recently concluded mid-term elections have provided a much-needed boost to the healthcare sector. New trends that the majority of healthcare companies are working on are also boosting the sector.

  • GlobeNewswire3 months ago

    Precipio ICE COLD-PCR™ Technology Selected by the University of Cincinnati Medical Center for Liquid Biopsy Study

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that its ICE COLD-PCR™ (ICP) technology has been selected for a screening study to identify clinically actionable mutations in non-small cell lung cancer (NSCLC) at the University of Cincinnati Medical Center. The study will focus on utilizing ICP mutation enrichment along with High Resolution Melt Analysis (HRM) screening technology to screen actionable mutations in epidermal growth factor receptor (EGFR) for NSCLC.

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks To Watch On Wednesday

    CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / Healthcare demand is increasing as an aging population continues to drive new healthcare market growth. The connection between healthcare goods and services is less tied to the economy compared to other sectors, and that could make healthcare stocks the place where investors will look for a hedge as the broader markets see increasing volatility. According to Bureau of Labor Statistics data*, the fastest-growing sectors include healthcare support occupations (23.2% increase from 2016-2026) and healthcare practitioners and technical occupations (15.2%), which entail home health aides, physician assistants and nurse practitioners, among other positions.

  • ACCESSWIRE6 months ago

    Precipio, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Precipio, Inc. (NASDAQ: PRPO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 23, 2018 at 9:00 AM Eastern Time. To ...